Priti Patel
About
Priti Patel is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology.
According to data from OpenAlex, Priti Patel has authored 57 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Genetics, 20 papers in Pathology and Forensic Medicine and 15 papers in Hematology. Recurrent topics in Priti Patel's work include Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (18 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Priti Patel is often cited by papers focused on Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (18 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Priti Patel collaborates with scholars based in United States, United Kingdom and Italy. Priti Patel's co-authors include Raquel Izumi, Min Hui Wang, John C. Byrd, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Jennifer R. Brown, Richard R. Furman, Paolo Ghia and Deborah M. Stephens and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Priti Patel
52 papers receiving 1.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Priti Patel United States | 17 | 841 | 699 | 411 | 301 | 269 | 57 | 1.2k | ||
| John N. Allan United States | 21 | 803 1.0× | 708 1.0× | 286 0.7× | 319 1.1× | 333 1.2× | 97 | 1.1k | ||
| Mehrdad Mobasher United States | 16 | 903 1.1× | 672 1.0× | 345 0.8× | 386 1.3× | 433 1.6× | 39 | 1.4k | ||
| Kerry A. Rogers United States | 20 | 1.1k 1.3× | 886 1.3× | 420 1.0× | 410 1.4× | 257 1.0× | 124 | 1.4k | ||
| Kathryn Humphrey United Kingdom | 16 | 1.0k 1.2× | 920 1.3× | 320 0.8× | 369 1.2× | 433 1.6× | 52 | 1.4k | ||
| Amber Gordon United States | 8 | 1.2k 1.4× | 792 1.1× | 357 0.9× | 535 1.8× | 340 1.3× | 14 | 1.5k | ||
| Karim Maloum France | 19 | 1.2k 1.4× | 920 1.3× | 336 0.8× | 612 2.0× | 205 0.8× | 51 | 1.6k | ||
| Maria Verdugo United States | 13 | 861 1.0× | 599 0.9× | 520 1.3× | 246 0.8× | 271 1.0× | 27 | 1.2k | ||
| Liana Gercheva Bulgaria | 15 | 707 0.8× | 417 0.6× | 765 1.9× | 209 0.7× | 194 0.7× | 46 | 1.3k | ||
| Sissy Peterman United States | 14 | 1.1k 1.3× | 806 1.2× | 271 0.7× | 322 1.1× | 277 1.0× | 16 | 1.3k | ||
| Marie‐Christine Kyrtsonis Greece | 18 | 497 0.6× | 421 0.6× | 471 1.1× | 177 0.6× | 392 1.5× | 81 | 1.1k |
Countries citing papers authored by Priti Patel
Since
Specialization
Citations
This map shows the geographic impact of Priti Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Priti Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Priti Patel more than expected).
Fields of papers citing papers by Priti Patel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Priti Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Priti Patel. The network helps show where Priti Patel may publish in the future.
Co-authorship network of co-authors of Priti Patel
This figure shows the co-authorship network connecting the top 25 collaborators of Priti Patel. A scholar is included among the top collaborators of Priti Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Priti Patel. Priti Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chan, Kenneth, Elizabeth Wahome, Alexios Antonopoulos, et al.. (2024). Coronary inflammation stratifies risk in patients undergoing coronary CT angiography: the Oxford Risk Factors and Non-Invasive Imaging (ORFAN) study. European Heart Journal. 45(Supplement_1).
2.
Nema, Rajeev, Ajay Kumar Singh, Priti Patel, et al.. (2023). Single Nucleotide Polymorphisms in Cytokine Genes are Associated with the Susceptibility to Oral Squamous Cell Carcinoma. Asian Pacific Journal of Cancer Prevention. 24(7). 2353–2360.
3.
Sharma, Shringi, Xavier Pépin, Jean Cheung, et al.. (2022). Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. British Journal of Clinical Pharmacology. 88(10). 4573–4584.
4.
Vishwanathan, Karthick, Helen Wei, Huan Liu, et al.. (2021). Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies. British Journal of Clinical Pharmacology. 88(5). 2284–2296.
5.
Izutsu, Koji, Kiyoshi Ando, Daisuke Ennishi, et al.. (2021). Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study. Cancer Science. 112(6). 2405–2415.
6.
Brown, Jennifer R., John C. Byrd, Paolo Ghia, et al.. (2021). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 107(6). 1335–1346.
7.
Rogers, Kerry A., Philip A. Thompson, John N. Allan, et al.. (2021). Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 106(9). 2364–2373.
8.
Kreitman, Robert J., Claire Dearden, Pier Luigi Zinzani, et al.. (2021). Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. Journal of Hematology & Oncology. 14(1). 35–35.
9.
Eyre, Toby A., Anna Schuh, William G. Wierda, et al.. (2021). Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study. The Lancet Haematology. 8(12). e912–e921.
10.
Comba, Andrea, Patrick Dunn, Padma Kadiyala, et al.. (2020). Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses. Neuro-Oncology. 22(6). 806–818.
11.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861.
12.
Cheung, Jean, Michael Gulrajani, Erika M. Gaglione, et al.. (2020). Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clinical Cancer Research. 26(12). 2800–2809.
13.
Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 136(Supplement 1). 16–18.
14.
Overman, Michael J., Milind Javle, R. Eric Davis, et al.. (2020). Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Journal for ImmunoTherapy of Cancer. 8(1). e000587–e000587.
15.
Awan, Farrukh T., Anna Schuh, Jennifer R. Brown, et al.. (2019). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Advances. 3(9). 1553–1562.
16.
Witzig, Thomas E., Kami J. Maddocks, Sven de Vos, et al.. (2019). Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 37(15_suppl). 7519–7519.
17.
Parashar, B., Priti Patel, Prabhsimranjot Singh, et al.. (2011). Management of Single Malignant Lung Nodules in Elderly Patients (70 Years or Older) Who are Not Candidates for Lobectomy. American Journal of Clinical Oncology. 35(5). 480–485.
18.
Patel, Priti & Sandy Srinivas. (2011). Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma. Current Clinical Pharmacology. 6(3). 181–188.
19.
Parashar, B., Priti Patel, Stefano Monni, et al.. (2010). Limited resection followed by intraoperative seed implantation is comparable to stereotactic body radiotherapy for solitary lung cancer. Cancer. 116(21). 5047–5053.
20.
Kallen, Alexander J., Michael A. Jhung, Steven Cheng, et al.. (2007). 112. American Journal of Kidney Diseases. 49(4). B52–B52.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by John N. Allan Breakdown of academic impact, for papers by Mehrdad Mobasher Breakdown of academic impact, for papers by Kerry A. Rogers Breakdown of academic impact, for papers by Kathryn Humphrey Breakdown of academic impact, for papers by Amber Gordon Breakdown of academic impact, for papers by Karim Maloum Breakdown of academic impact, for papers by Maria Verdugo Breakdown of academic impact, for papers by Liana Gercheva Breakdown of academic impact, for papers by Sissy Peterman Breakdown of academic impact, for papers by Marie‐Christine Kyrtsonis